# US 2018/0021302 A1 · Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021302 A1
- Document ID: US20180021302A1
- Status: Published application
- Kind: A1
- Application number: 15/549,401
- Filed: 2016-02-12
- Published: 2018-01-25
- Earliest claimed: 2015-02-13
- Assignees: Institut National De La Sante Et De La Recherche Medicale (Inserm); Universite Paris Diderot—Paris 7
- Applicants: Institut National De La Sante Et De La Recherche Medicale (Inserm); Université Paris Diderot - Paris 7
- Inventors: Nicolas CHARLES; Christophe PELLEFIGUES
- Web page: https://patentgrep.com/patent/US20180021302A1

## CPC

- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2300/00: Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns a PTGDR-1 antagonist, a PTGDR-2 antagonist, a dual PTGDR-1/PTGDR-1 antagonist, or a combination of PTGDR-1 antagonist and PTGDR-2 antagonist, and pharmaceutical compositions containing them, for use for preventing and/or treating SLE.

## Claims

### Claim 1

A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said antagonist is a small molecule antagonist.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said antagonist has formula (I)
or pharmaceutically acceptable salts thereof, wherein n is 0 or 1; m is 1, 2 or 3; R1 is H, C1-C3 alkyl, halogenated C1-C3 alkyl or cyclopropyl; R2 is 4-chlorophenyl or 2,4,6-trichlorophenyl.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said PTGDR-1 antagonist is laropiprant.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said PTGDR-1 antagonist is used in combination with at least a PTGDR-2 antagonist.

### Claim 6 (depends on 5)

The method according to claim 5, wherein said PTGDR-2 antagonist has formula formula (VIII)
wherein R1 is H, fluorine, methyl, methoxy, benzyloxy, or hydroxyl,
R2 is phenyl which is substituted by fluorine, chlorine, trifluoromethyl, methyl, ethyl, propyl, isopropyl, or methoxy, and
Y is 0 or 1,
or pharmaceutically acceptable salts thereof.

### Claim 7 (depends on 6)

The method according to claim 6, wherein said PTGDR-2 antagonist is CAY10471 (TM30089).

### Claim 8 (depends on 5)

The method according to claim 5, wherein said PTGDR-1 antagonist and PTGDR-2 antagonist are formulated in a single pharmaceutical composition.

### Claim 9 (depends on 5)

The method according to claim 5, wherein said PTGDR-1 antagonist and PTGDR-2 antagonist are formulated in separate pharmaceutical compositions for simultaneous use, separate use, or use spread over time.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said PTGDR-1 antagonist is a dual PTGDR-1/PTGDR-2 antagonist.

### Claim 11

A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a pharmaceutical composition comprising a PTGDR-1 antagonist and a PTGDR-2 antagonist, or a dual PTGDR-1/PTGDR-2 antagonist.

### Claim 12

A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-1 antagonist and a PTGDR-2 antagonist as a combined preparation for simultaneous use, separate use, or use spread over time.

### Claim 13

A method for preventing and/or treating SLE in a patient in need thereof, wherein said method comprises administering said patient with a PTGDR-2 antagonist.

### Claim 14 (depends on 1)

The method according to claim 1, wherein the PTGDR-1 antagonist prevents basophil homing to secondary lymphoid organs.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the PTGDR-1 antagonist prevents, limits the extent or reduces the increase in autoantibody titers and/or the occurrence of SLE flares and/or organ damages.
